Puerta de Hierro Majadahonda University Hospital Boadilla del Monte, Spain
Disclosure information not submitted.
Olga Rusinovich1, Enrique Calvo-Aranda2, Claudia Maria Gomez2, Patricio Cardoso Peñafiel2, Pilar Navarro Alonso3, Miguel Cantalejo Moreira4, Alberto Diaz y Oca3, Pablo Navarro5, Maria Machattou5, Maria Alonso5, Carlota Navarro5, Carolina Merino5, Hilda Godoy6, Maria Carmen Barbadillo Mateos7, Carlos Isasi5, Maria Perez Ferro8, Jessica Polo9, Veronica Garcia10, Jose Luis Andreu-Sánchez11, Jose Campos12 and Jesus Sanz13, 1Puerta de Hierro Majadahonda University Hospital, Boadilla del Monte, Spain, 2Hospital Universitario Infanta Leonor, Madrid, Spain, 3Fuenlabrada University Hospital, Madrid, Spain, 4Hospital Universitario de Fuenlabrada, Madrid, Spain, 5Puerta de Hierro Majadahonda University Hospital, Madrid, Spain, 6Hospital Universitario Puerta de Hierro, Madrid, Spain, 7Public, Madrid, Spain, 8Hospital Universitario Rey Juan Carlos, Madrid, Spain, 9Rey Juan Carlos University Hospital, Madrid, Spain, 10Ramon y Cajal University Hospital, Madrid, Spain, 11Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, 12Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, 13Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Rituximab (RTX) is a murine/human chimeric monoclonal antibody directed against the CD20 receptor expressed on pre-B and mature B cells. Rituximab is used effectively in the treatment of different rheumatic diseases, but it can induce hypogammaglobulinemia as a side effect. The purpose of our study was to analyze the prevalence of hypogammaglobulinemia and its association with infections in patients with rheumatic diseases treated with RTX.
Methods: Multicenter, retrospective, observational study. Patients with rheumatic diseases treated with RTX in 4 centers in Madrid, in which serum immunoglobulin counts were available were included. Demographic and clinical variables of the sample were analyzed, changes in immunoglobulin G concentrations during treatment from baseline were assessed. The chi-square test was used to examine the relationship between variables, considering a p value < 0.05 as statistically significant. Logistic regression models were used to analyze the association between hypogammaglobulinemia and sample characteristics.
Results: One hundred and seven patients were included: 18 men (16.8%) and 89 women (83.2%), with a mean age of 55.9 (±13.9) years, a mean disease duration of 13.1 (±0.8) years, and a mean age of 51 (±14.4) years at the start of treatment. The most prevalent diagnoses were rheumatoid arthritis (RA) (50.5%), primary Sjogren's syndrome (pSS) (10.3%), and systemic lupus erythematosus (SLE) (10.3%). Fourteen (13%) patients were treated with RTX monotherapy. The rest of the patients received concomitant treatment with other immunomodulators such as corticosteroids (64.5%), methotrexate (29%), hydroxychloroquine (27%), leflunomide (9.3%), sulfasalazine (1.9%), or mycophenolate mofetil (2.8%). Twelve (11.21%) patients developed hypogammaglobulinemia (IgG< 600 mg/dl): 6 (50%) had RA, 1 (8.3%) SLE, 1 (8.3%) ANCA vasculitis, 1 (8.3%) leukocytoclastic vasculitis, 1 (8.3%) IgG4-related disease, 1 (8.3%) dermatomyositis, and 1 (8.3%) pSS. Patients with hypogammaglobulinemia had significantly lower mean serum IgG concentrations at the start of treatment (876.3 vs 1249.4 mg/dl; p=0.05). In the multivariate analysis no variable related to hypogammaglobulinemia was found. Fifty-three (49.5%) patients presented infection, of which 17 (15.9%) were serious infections (those that required admission). The distribution of infection by groups (patients with and without hypogammaglobulinemia) is shown in Table 1. No significant differences were found in the development of infections or serious infections between patients with and without hypogammaglobulinemia. Only corticosteroid doses equivalent to ≥7.5 mg/day of prednisone were found as a risk factor for the development of infections (OR 3.48, 95% CI: 1.20-0.11; p=0.02).
Conclusion: Patients with hypogammaglobulinemia had significantly lower mean IgG concentrations at the start of treatment with RTX than those who did not develop it. No greater frequency or severity of infections was observed between patients with and without hypogammaglobulinemia. Prednisone equivalent daily dose ≥7.5 mg/day was a risk factor for occurrence of infections. Larger sample size studies are needed to confirm these findings.
Table 1. Hypogammaglobulinemia and infections in patients with rheumatic diseases treated with Rituximab.
O. Rusinovich: None; E. Calvo-Aranda: None; C. Gomez: None; P. Cardoso Peñafiel: None; P. Navarro Alonso: None; M. Cantalejo Moreira: None; A. Diaz y Oca: None; P. Navarro: None; M. Machattou: None; M. Alonso: None; C. Navarro: None; C. Merino: None; H. Godoy: None; M. Barbadillo Mateos: None; C. Isasi: None; M. Perez Ferro: None; J. Polo: None; V. Garcia: None; J. Andreu-Sánchez: None; J. Campos: None; J. Sanz: AbbVie/Abbott, 1, 6, Janssen, 1, 5, 6, Novartis, 6, UCB, 1, 5, 6.